Literature DB >> 34424598

Targeting the Myddosome in Systemic Autoimmunity: Ready for Prime Time?

Mariana J Kaplan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34424598      PMCID： PMC8985185          DOI： 10.1002/art.41951

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   15.483


× No keyword cloud information.
  16 in total

Review 1.  An update on the role of type I interferons in systemic lupus erythematosus and Sjögren's syndrome.

Authors:  Gudny Ella Thorlacius; Marie Wahren-Herlenius; Lars Rönnblom
Journal:  Curr Opin Rheumatol       Date:  2018-09       Impact factor: 5.006

2.  Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity.

Authors:  Shailesh Dudhgaonkar; Sourabh Ranade; Jignesh Nagar; Siva Subramani; Durga Shiv Prasad; Preethi Karunanithi; Ratika Srivastava; Kamala Venkatesh; Sabariya Selvam; Prasad Krishnamurthy; T Thanga Mariappan; Ajay Saxena; Li Fan; Dawn K Stetsko; Deborah A Holloway; Xin Li; Jun Zhu; Wen-Pin Yang; Stefan Ruepp; Satheesh Nair; Joseph Santella; John Duncia; John Hynes; Kim W McIntyre; Julie A Carman
Journal:  J Immunol       Date:  2016-12-21       Impact factor: 5.422

Review 3.  Novel role and regulation of the interleukin-1 receptor associated kinase (IRAK) family proteins.

Authors:  Ying Su Huang; Anna Misior; Li Wu Li
Journal:  Cell Mol Immunol       Date:  2005-02       Impact factor: 11.530

Review 4.  Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis.

Authors:  Michael D Wiese; Arkady T Manning-Bennett; Ahmad Y Abuhelwa
Journal:  Expert Opin Investig Drugs       Date:  2020-04-17       Impact factor: 6.206

Review 5.  Bite of the wolf: innate immune responses propagate autoimmunity in lupus.

Authors:  Sarthak Gupta; Mariana J Kaplan
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

6.  TLR7 Protein Expression in Mild and Severe Lupus-Prone Models Is Regulated in a Leukocyte, Genetic, and IRAK4 Dependent Manner.

Authors:  Teja Celhar; Hao Kim Lu; Lia Benso; Larissa Rakhilina; Hui Yin Lee; Shubhita Tripathi; Olga Zharkova; Wei Yee Ong; Hiroko Yasuga; Bijin Au; Damien Marlier; Lina Hsiu Kim Lim; Thomas Paulraj Thamboo; John S Mudgett; Matthew F Mackey; Dennis M Zaller; John E Connolly; Anna-Marie Fairhurst
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

7.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.

Authors:  Spencer I Danto; Negin Shojaee; Ravi Shankar P Singh; Cheryl Li; Steven A Gilbert; Zorayr Manukyan; Iain Kilty
Journal:  Arthritis Res Ther       Date:  2019-12-05       Impact factor: 5.156

8.  IRAK4 inhibition: a promising strategy for treating RA joint inflammation and bone erosion.

Authors:  Sadiq Umar; Karol Palasiewicz; Katrien Van Raemdonck; Michael V Volin; Bianca Romay; M Asif Amin; Ryan K Zomorrodi; Shiva Arami; Mark Gonzalez; Vikram Rao; Brian Zanotti; David A Fox; Nadera Sweiss; Shiva Shahrara
Journal:  Cell Mol Immunol       Date:  2020-05-15       Impact factor: 22.096

9.  Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease.

Authors:  Christian Lood; Luz P Blanco; Monica M Purmalek; Carmelo Carmona-Rivera; Suk S De Ravin; Carolyne K Smith; Harry L Malech; Jeffrey A Ledbetter; Keith B Elkon; Mariana J Kaplan
Journal:  Nat Med       Date:  2016-01-18       Impact factor: 53.440

Review 10.  Regulation of the nucleic acid-sensing Toll-like receptors.

Authors:  Nicholas A Lind; Victoria E Rael; Kathleen Pestal; Bo Liu; Gregory M Barton
Journal:  Nat Rev Immunol       Date:  2021-07-16       Impact factor: 108.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.